GlassScriptPhysician profile
Michael J Tracz
NPI 1528032521
$10,297.23
in general payments reported to CMS, 2019-2025
40 companies · $1,507 in 2025
The $1,507 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $560 · 2021: $1,167 · 2022: $2,274 · 2023: $2,408 · 2024: $1,782 · 2025: $1,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,530 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,529.73 |
| Education | $166.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,259.29 | 2019-2025 | Veltassa |
| Amgen INC. | $1,175.74 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $1,102.80 | 2019-2025 | Farxiga, Flumist Quadrivalent, Lokelma |
| Aurinia Pharma U.S., INC. | $930.51 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $670.18 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $543.95 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $443.07 | 2020-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $434.95 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.73 | 2021-2025 | Jardiance, Synjardy |
| Fresenius USA Marketing, INC. | $342.91 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $281.23 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $217.31 | 2020-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $215.10 | 2019-2023 | |
| Glaxosmithkline, LLC. | $197.48 | 2021-2024 | Benlysta, Jesduvroq, Shingrix |
| Novartis Pharmaceuticals Corporation | $184.08 | 2024-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tracz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.